Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 Annual Meeting

Viewing 1-12 of 12 articles

SNMMI 2026: Baseline PSMA PET Tumor Volume Predicts Overall Survival with 177Lu-PSMA-I&T in Individual mCRPC patients: A Single-Center Real-World Study

SNMMI 2026: The LuRa Study: Safety and Survival Outcomes of Radium-223 in Patients with mCRPC with Prior 177Lu-PSMA Radioligand Therapy

SNMMI 2026: The REFINE Study – A Prospective Clinical Trial: Uncovering Prostate Cancer Biochemical Recurrence with 18F-Fluciclovine After Negative PSMA PET

SNMMI 2026: Survival in Veterans with Metastatic Hormone Sensitive Prostate Cancer Based on PSMA PET/CT Imaging

SNMMI 2026: First in Human CD46-Targeted ImmunoPET Imaging with 89Zr-DFO-YS5 in mCRPC

SNMMI 2026: Olaparib Sensitizes Prostate Cancer to 177Lu-PSMA-617 Radioligand Therapy via Suppression of Glycolysis

SNMMI 2026: Head to Head Comparison of 68Ga-OncoACP3 and 68Ga-PSMA-11 PET for Imaging Prostate Cancer

SNMMI 2026: Longitudinal Outcomes of PSMA PET/CT-Detected Bone Oligometastases: A Two-Center Study

SNMMI 2026: Metabolic Tumor Phenotype Determines Radiation Delivery and Outcomes in PSMA Radiopharmaceutical Therapy for Advanced Prostate Cancer

SNMMI 2026: Renal Function Stability in Patients Treated with 177Lu-PSMA-617: A Longitudinal Analysis of eGFR and Creatinine Trends During and After Therapy

SNMMI 2026: Safety and Efficacy of Rechallenge PSMA Radioligand Therapy in Post-Taxane mCRPC: An Early Single Center Experience

SNMMI 2026: Immunological Priming Improves Efficacy of 177Lu-PSMA-617 in mCRPC: A Retrospective Cohort Study